Ticker
ABUSCompany Name
ARBUTUS BIOPHARMA CORPSector
HealthcareIndustry
BiotechnologyExchange
NASDAQDate | Capital Expenditure | Free Cash Flow | Net Cash Flow - Operations |
---|---|---|---|
6/30/2025 | $ 77K | $ -60.27M | $ -60.19M |
3/31/2025 | $ 87K | $ -59.03M | $ -58.95M |
12/31/2024 | $ 182K | $ -65.03M | $ -64.85M |
9/30/2024 | $ 96K | $ -71.92M | $ -71.83M |
6/30/2024 | $ 108K | $ -72.98M | $ -72.88M |
3/31/2024 | $ 966K | $ -78.9M | $ -77.93M |
12/31/2023 | $ 988K | $ -86.92M | $ -85.94M |
9/30/2023 | $ 1.14M | $ -86.78M | $ -85.63M |
6/30/2023 | $ 1.22M | $ -83.76M | $ -82.54M |
3/31/2023 | $ 554K | $ -83.83M | $ -83.28M |
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
CF - Operations - CapEx
(=) FCF
FCF for ARBUTUS BIOPHARMA CORP is calculated as follows: CF - Operations [ $ -49.78M ] - CapEx [ $ 140K ]
(=) FCF [ $ -49.92M ]
Minimum
Dec 31, 2023
Maximum
Mar 31, 2022
Average
Median
filtered constituents | 3.3K |
---|---|
min | $ -356.66M |
max | $ 390M |
average | $ 28.75M |
median | $ 461K |
std | $ 117.92M |